Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics Inc.

Spyre Therapeutics, Inc ($SYRE) announced an update on their ongoing clinical study. Spyre Therapeutics, Inc. is running a long-term study to track...

Spyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study

Spyre Therapeutics ( ($SYRE) ) just unveiled an announcement. On June 15, 2026, Spyre Therapeutics reported positive 12-week induction topline resu...

Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Cogstate Ltd (COGZF) w...

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)

The latest announcement is out from Spyre Therapeutics ( ($SYRE) ). On May 27, 2026, Spyre Therapeutics held its Annual Meeting of Stockholders, at...

Market Cap	$1.65B	P/E Ratio	N/A
52W High	$90.99	52W Low	$14.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	56.9%	52W Position	96.6%
Overall Score	57	Value Score	60
Quality Score	21	Technical Score	91

EPS Current Est	$-2.86	EPS Next Est	$-3.31
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SYRE	$88.34	+0.97%	2.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SYRE	$88.34	+1.0%	2.42M
3
4
5
6

SYRE

SYRE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Spyre Therapeutics Inc. Data in Excel

Get Spyre Therapeutics Inc. Data in Excel